TACTICAL THERAPEUTICS’ first drug candidate, CTO has unique properties of improved bioavailability and delivery to target cells, improved efficacy in inhibiting tumors and higher clearance rate and reduced toxicity (compared with a related drug, CAI, abandoned by the NCI).  CTO is being developed on the Fast Track.